	US 12,461,099 B2
	Immunoreactive polypeptides
Jere McBride, Galveston, TX (US); and David H. Walker, Galveston, TX (US)
Assigned to Research Development Foundation, Carson City, NV (US)
Appl. No. 17/053,539
Filed by Research Development Foundation, Carson City, NV (US)
PCT Filed May 7, 2019, PCT No. PCT/US2019/031137 § 371(c)(1), (2) Date Nov. 6, 2020, PCT Pub. No. WO2019/217435, PCT Pub. Date Nov. 14, 2019.
Claims priority of provisional application 62/667,925, filed on May 7, 2018.
Prior Publication US 2021/0239695 A1, Aug. 5, 2021
Int. Cl. G01N 33/569 (2006.01); A61K 31/65 (2006.01); C07K 14/29 (2006.01); G01N 33/543 (2006.01)

CPC G01N 33/56911 (2013.01) [A61K 31/65 (2013.01); C07K 14/29 (2013.01); G01N 33/54346 (2013.01); G01N 2333/29 (2013.01); G01N 2469/20 (2013.01)]

8 Claims

1. A method of detecting antibodies that specifically bind an Ehrlichia organism in a test sample, comprising:

(a) contacting an isolated polypeptide of Ecaj_0919, Ecaj_0073, Ecaj_0104, Ecaj_0663, A77 (SEQ ID NO:22), A62 (SEQ ID NO:17), A56 (SEQ ID NO:16), A19 (SEQ ID NO:6), A50 Ech_0700; SEQ ID NO: 28), A51 (SEQ ID NO:13), A14 (SEQ ID NO:4), A63 (SEQ ID NO:18), A34 (SEQ ID NO:9), A9 (SEQ ID NO:3), A42 (Ech_0240; SEQ ID NO:11), with the test sample, under conditions that allow peptide-antibody complexes to form;

(b) detecting the peptide-antibody complexes; wherein the detection of the peptide-antibody complexes is an indication that antibodies specific for an Ehrlichia organism are present in the test sample, and wherein the absence of the peptide-antibody complexes is an indication that antibodies specific to an Ehrlichia organism are not present in the test sample.